In the 2018 ASBMR annual meeting, many important results were reported, showing the effects of anti-osteoporotic drugs already focusing on bone quality and the concept of "treat-to-target", although there were few big topics on novel drugs. However, some reports on new drugs, such as probiotics and SARM(selective androgen receptor modulator), did draw attention.